EQL Pharma strengthens its organization with Alexander Brising, New Business Development Director
EQL Pharma has recruited Alexander Brising as head of business development at EQL Pharma. He joined the company in mid-November 2016. Alexander Brising will lead the work to identify new products for in-licensing or in-house development and thus strengthen an already strong pipeline of niche generics.
Alexander Brising has a background from leading assignments in the pharmaceutical industry. Recently he was part of the management team at Sandoz Nordic headquarter in Copenhagen, where he had budget responsibility for retail in Sweden. He has an MBA from the Gothenburg School of Economics.
"To take on the position as head of Business Development at EQL Pharma is as a very exciting opportunity. EQLs mission to develop niche generics is very interesting, and I think my strong background in business development and in identifying product candidates with high potential, is a perfect match, "says Alexander Brising.
"EQL Pharma continues to focus on putting new niche generics on the market. In this effort Alexander Brising will play a key role ", says Christer Fåhraeus, CEO of EQL Pharma.
For further information, please contact:
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
EQL Pharma AB (publ) in brief
EQL Pharma is specialized in developing and selling generic drugs, ie drugs that are medically equivalent to the original medicines. The company currently markets five niche generics in the Swedish and Danish markets, in addition to these, there are a significant pipeline of additional niche generics for launch in 2017 and onwards. The business is currently focused entirely on prescription drugs in the Nordic region. EQL Pharma is based in Lund, employs seven (7) people and is listed on AktieTorget. EQL Pharma conducts extensive development in cooperation with leading contract manufacturers and major pharmaceutical companies in countries including India and Chin